Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 234-634-6 | CAS number: 12018-10-9
Endpoint summary
Administrative data
Description of key information
A guideline-compliant and GLP-compliant acute study is available for the material 'Chromoxyd Dyko' (containig 96% chromium oxide), which shows low acute oral toxicity; similar findings are seen in two additional proprietary studies performed with chromium oxide and chromium hydroxide. No information is available on acute dermal toxicity. The results of a modern, proprietary GLP and guideline-compliant study (Gaunt, 2009) reports an LC50 value of >5.41 mg/L.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Dose descriptor:
- LD50
- Value:
- 5 000 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Dose descriptor:
- LC50
- Value:
- 5 410 mg/m³ air
Additional information
Acute oral toxicity
The acute oral LD50 of 'Chromoxyd Dyko' (96% chromium oxide, 4% titanium dioxide) in the rat was found to be >5000 mg/kg bw in a guideline- and GLP-compliant study (Bomhard, 1988). Titanium dioxide is known to be toxicologically inert and can therefore be disregarded for the purposes of this study.
The acute oral LD50 of 'Chromoxid Extra' (chromium hydroxide) was also found to be >5000 mg/kg bw (Loeser, 1981). The results of this study, performed with a similar Cr (III) salt of low water solubility can be extrapolated to chromium oxide.
In a further study, the acute oral LD50 of 'Chromoxid Grun GN' (chromium oxide) was found to be >15000 mg/kg bw (Loeser, 1972). This further confirms the low acute toxicity of the substance.
Acute dermal toxicity
No information is available on acute dermal toxicity, however based on the very low acute oral toxicity and very low dermal penetration, toxicity by this route can confidently be predicted to be very low. No testing is therefore proposed, based on scientific and animal welfare considerations.
Acute inhalation toxicity
The results of a modern, proprietary GLP and guideline-compliant study (Gaunt, 2009) reports an LC50 value of >5.41 mg/L.
Justification for classification or non-classification
Chromium oxide is not listed on Annex I of Directive 67/548/EEC.
It is not proposed to classify chromium oxide for acute oral or inhalation toxicity (based on experimental results) or for acute dermal toxicity (based on scientific consideration).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
